The Polycomb Group Protein EZH2 Impairs DNA Damage Repair Gene Expression in Human Uterine Fibroids

Area of Science:

• Gynecology
• Molecular Biology
• Epigenetics

Background:

• Uterine fibroids (UFs) are common benign smooth muscle tumors affecting a majority of women.
• The precise cellular and molecular mechanisms driving UF development remain unclear.
• Genetic abnormalities in UFs suggest a potential role for impaired DNA damage repair capacity.

Purpose of the Study:

• To investigate alterations in DNA damage repair gene expression in UFs.
• To explore the regulatory mechanisms, including the role of enhancer of zeste homolog 2 (EZH2), in UF pathogenesis.
• To assess the therapeutic potential of targeting EZH2 in UF treatment.

Main Methods:

• Comparative analysis of DNA repair gene (RAD51, BRCA1) expression in fibroid and myometrial tissues.
• Immunohistochemistry and Western blot to evaluate EZH2 protein levels.
• In vitro studies using EZH2 inhibitors on fibroid cells.
• Assessment of epigenetic modifications (histone methylation) at gene promoter regions.

Main Results:

• RAD51 and BRCA1 expression levels were altered in fibroid tissues compared to adjacent myometrium.
• Higher EZH2 expression was observed in a subset of fibroids.
• EZH2 inhibition increased RAD51 and BRCA1 expression, reduced fibroid cell proliferation, and induced cell cycle arrest.
• Restoration of RAD51 and BRCA1 expression by EZH2 inhibition was linked to decreased histone 3 lysine 27 trimethylation.

Conclusions:

• EZH2 plays a significant role in UF biology by regulating DNA damage repair genes through histone methylation.
• Targeting EZH2 may offer a novel therapeutic strategy for symptomatic uterine fibroids.
• Further research into EZH2-mediated epigenetic regulation could uncover new treatment avenues for UFs.